Welcome to our dedicated page for BioSig Technologies SEC filings (Ticker: BSGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BSGM SEC filings archive on Stock Titan presents the regulatory record of the company formerly known as BioSig Technologies, Inc., which has since rebranded as Streamex Corp. and now trades under the symbol STEX. These documents trace the company’s transition from a medical device technology issuer to a business focused on real-world asset and gold tokenization.
Key filings include multiple Current Reports on Form 8-K detailing material events such as the merger with Streamex Exchange Corporation, the amendment to the certificate of incorporation changing the corporate name to Streamex Corp., and the Nasdaq ticker symbol change from BSGM to STEX. Other 8-K filings describe the secured convertible debenture purchase agreement with an institutional investor, the issuance of an initial tranche of convertible debentures, and related security and registration rights agreements.
The archive also contains a definitive proxy statement on Form DEF 14A for the company’s annual meeting, which outlines proposals including director elections, executive compensation advisory votes, auditor ratification, and amendments to the long-term incentive plan. Additional filings report amendments to the certificate of incorporation to increase authorized shares and to classify the board into staggered terms, as well as a tokenized yield partnership agreement related to precious-metal lease and bond programs.
On Stock Titan’s filings page, investors can review these historical BSGM documents alongside AI-powered summaries that explain the main terms, structures, and implications of each report. The feed updates as new Streamex Corp. (STEX) filings appear in the SEC’s EDGAR system, allowing users to follow the company’s ongoing regulatory disclosures, including future 10-K annual reports, 10-Q quarterly reports, and any Form 4 insider transaction filings associated with the successor entity.
The filing is an initial Form 3 by Frank Giustra reporting indirect beneficial ownership in Streamex Corp. (STEX). Mr. Giustra beneficially holds 17,193,640 Exchangeable Shares that are exchangeable into Common Stock of the issuer. Approximately 5.01% of the Exchangeable Shares are currently exchangeable into Common Stock, with the remaining Exchangeable Shares becoming exchangeable upon a pending stockholder approval expected within 60 days. Nasdaq rules limit exchanges to 19.9% of outstanding Common Stock until stockholder approval is obtained.
BioSig Technologies, Inc. filed an amendment to its certificate of incorporation to change its corporate name to Streamex Corp. This Name Change was approved by the Board of Directors and, according to the company, does not affect the rights of existing security holders.
Effective before the open of trading on September 12, 2025, the company’s common stock will stop trading under its prior ticker and begin trading on the Nasdaq Stock Market under the new symbol “STEX”. The CUSIP number will remain the same, and existing stock certificates with the old corporate name will continue to be valid, with new certificates issued over time as shares are exchanged or transferred.
Under Section 242 of the Delaware General Corporation Law, stockholder approval was not required for this Name Change. The company also issued a press release on September 10, 2025 announcing the new name and ticker, which has been furnished as an exhibit.
BioSig Technologies, Inc. entered a three-year Tokenized Yield Partnership Agreement with Monetary Metals & Co. to create and distribute blockchain-based products that tokenize yield from precious-metal lease and bond programs. The partnership includes mutual exclusivity for tokenizing yield from precious-metal leases, subject to volume-based performance thresholds and a ninety-day cure period if supply falls short. Each quarter, BioSig must supply at least 10% of qualifying leased ounces, while Monetary Metals will offer at least 90% of the gold under management supplied by BioSig as Passing Leases. BioSig will receive discounted fees and quarterly cash rebates on gold purchases, plus a quarterly revenue share of 0.35% to 0.50% on supplied gold deployed in Passing Leases, and will own the intellectual property for the tokenized yield products.
BioSig Technologies, Inc. (BSGM) filed an Form 8-K dated September 5, 2025 reporting corporate governance actions. The filing lists Item 5.03 (submission of matters to a vote of security holders) and includes two exhibits: a Ninth Certificate of Amendment (Exhibit 3.1) and an Incentive Plan Amendment (Exhibit 10.1). The cover page also references an Inline XBRL interactive data file. The form is signed by Karl Henry McPhie, Chief Executive Officer.
BioSig Technologies, Inc. completed an underwritten public stock offering of 3,852,149 shares of common stock at $3.90 per share. This transaction is expected to generate aggregate gross proceeds of approximately $15.02 million before underwriting discounts, commissions, and expenses.
The company plans to use the net proceeds to purchase gold bullion under its investment policy, and for working capital and general corporate purposes. BioSig, its officers, directors, and certain stockholders agreed to 90-day lock-up arrangements that restrict most additional share offerings or transfers during that period. The deal was conducted under an existing Form S-3 shelf registration and supported by a legal opinion on the validity of the shares.
BioSig Technologies (BSGM) reported a substantial net loss of $20,368 and $23,169 for the three- and six-month periods presented, respectively, and a working capital deficit of $110 million, which management states raises substantial doubt about the company’s ability to continue as a going concern. The balance sheet includes a $105,498 derivative/Exchangeable Shares liability that remains classified as a liability because shareholder approval and other contingencies have not been resolved. The company completed the acquisition of Streamex, recording $57.8 million of goodwill and material intangible assets (developed technology and legal/compliance framework). Financing and equity activity during the period included multiple stock offerings, an at-the-market program raising net proceeds of about $3.88 million, and extensive issuance of common stock, RSUs, warrants, and preferred cumulative dividends recorded.
BioSig Technologies, Inc. filed an amendment to its 2025 special meeting proxy to update details of its Yorkville financing and its Streamex acquisition proposals. The company revised its secured convertible debenture purchase agreement with Yorkville so that there are now two secured convertible debentures of $25 million each, with up to an additional $50 million of debentures issuable only by mutual agreement, all sold at 96% of principal in a private placement. At the floor conversion price of $1.8828 per share, converting $50 million of debentures would require issuing about 26,556,193 shares, which could exceed 20% of shares outstanding on July 7, 2025, so stockholder approval is required under Nasdaq rules. The amendment also updates the illustrative dilution table, clarifies that failure to approve Proposal 2 would block the sale of the debentures and could constrain working capital, refines the vote treatment for Proposal 1, and removes references to financial advisors to state that none were engaged for the Streamex deal.
BioSig Technologies, Inc. is offering shares of common stock and pre-funded warrants exercisable at $0.001 per share; the company reported a last Nasdaq sale of $4.67 per share on August 12, 2025. Following its May 28, 2025 acquisition of Streamex, BioSig now operates two segments: its PURE EP medical device/software platform and a tokenized finance/RWA digitization business through Streamex. BioSig reports an extensive patent estate (including 42 issued/allowed utility patents, 31 utility applications pending, and 30 design patents) related to PURE EP.
Preliminary unaudited results for the six months ended June 30, 2025 show substantial losses: net loss of $23,200 (in thousands), operating expenses of $23,300 (in thousands), stock-based compensation of $7,400 (in thousands), and cash and cash equivalents of $2,800 (in thousands). Streamex generated approximately $200,000 in revenue for the three months ended March 31, 2025. Material financing and corporate actions disclosed include the issuance of 109,070,079 Exchangeable Shares, a proposed up-to-$50 million Convertible Debenture financing with Yorkville, and several shareholder proposals required to implement the Share Exchange—all of which could cause significant dilution and depend on stockholder approvals.